Richard Thomas Williams - Feb 11, 2022 Form 4 Insider Report for Kinnate Biopharma Inc. (KNTE)

Signature
/s/ Mark A. Meltz, attorney in fact
Stock symbol
KNTE
Transactions as of
Feb 11, 2022
Transactions value $
$0
Form type
4
Date filed
2/15/2022, 03:00 PM
Next filing
Mar 15, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNTE Employee Stock Option (right to buy) Award $0 +135K $0.00 135K Feb 11, 2022 Common Stock 135K $10.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2022 (the "Vesting Commencement Date") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2026, subject to the Reporting Person continuing to be a service provider through each such date.